{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 0,
        "end": 9
      }
    },
    {
      "id": "T3",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 48,
        "end": 52
      }
    },
    {
      "id": "T4",
      "obj": "Disease",
      "span": {
        "begin": 241,
        "end": 253
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 167,
        "end": 179
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 48,
        "end": 68
      }
    },
    {
      "id": "T10",
      "obj": "Chemical",
      "span": {
        "begin": 76,
        "end": 98
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "23792568_2",
  "text": "Sorafenib , the first agent developed to target BRAF mutant melanoma , is a multi-kinase inhibitor that was approved by the FDA for therapy of kidney and subsequently liver cancer , and is currently in clinical trials for thyroid , lung and brain cancer ."
}
